Form 4: RAPT Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Michael F. Giordano, a director of RAPT Therapeutics, acquired stock options on May 22, 2024.
Summary
- On May 22, 2024, Michael F. Giordano, a director of RAPT Therapeutics, acquired stock options.
- The stock options grant the right to buy 36,490 shares of RAPT Therapeutics common stock at an exercise price of $4.63.
- The options vest in 12 equal monthly installments from the grant date.
- The options expire on May 21, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
This Form 4 filing does not contain any forward-looking statements regarding the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC when company insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of the stock option transaction. |
| 05/21/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.